![](https://www.businessmarketinsights.com/assets/img/reports-icon.png)
North America Acute Lung Injury Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Therapy (Mechanical Ventilation, Fluid Management, Pharmacotherapy, and Adjunctive Procedures) and End User (Hospitals, Ambulatory Surgery Centers, and Others)
Market Introduction
North American market for acute lung injury consists of the US, Canada, and Mexico. The US is the largest market for acute lung injury, followed by Canada and Mexico. The market across the US is expected to grow due to the well-established infrastructure, increasing prevalence of Acute Lung Injury and other lung diseases. Lung diseases like chronic obstructive pulmonary disease (COPD) and acute lung injury are the third leading cause of death in the US. Pneumonia is the direct cause of acute lung injury. According to the American Thoracic Society (ATS), pneumonia is the most common cause of sepsis and shock, causing 50% of all episodes. Pneumonia is a very common reason for US children being hospitalized. Every year, almost 1 million individuals in the United States seek hospital treatment for pneumonia, and 50,000 people die as a result of the illness. Also, according to National Hospital Ambulatory Medical Care Survey: 2018, the Annual number and percent distribution of emergency department visits by the Pneumonia diagnosis group in the United States was 1485. Market players are adopting organic and inorganic growth strategies for market development. For instance, in September 2020, Stemedica Cell Technologies, Inc. received US FDA investigational new drug (IND) approval for Phase II, controlled study for safety, tolerability, and efficacy assessment of intravenous allogeneic mesenchymal stem cells in patients with acute to severe lung injury due to COVID-19. Thus, owing to the factors mentioned above, it is expected that the acute lung injury market is likely to propel exponentially during the forecast years.
In case of COVID-19, North America is highly affected especially the US. The high number of COVID cases have resulted in a negative impact on country’s and region’s economy and there has been a decline in overall business activities and growth of various industries operating in the region. Market players are initiated clinical trials for the drug development of acute lung injury. For instance, Chimerix, a biopharmaceutical company initiated a Phase II/III clinical trial in June 2020 for to evaluate the safety and efficacy of Dociparstat sodium (DSTAT) in patients with Acute Lung Injury (ALI) due to COVID-19. DSTAT is a glycosaminoglycan derivative of heparin with robust anti-inflammatory properties. Chimerix completes enrolment in its phase II part of phase II/III trial for acute lung injury. The Phase 2 portion of the study will enroll 24 subjects to confirm the maximum safe dose and then expand it to 50 patients at the selected dose. Contingent upon positive results, the Phase 3 portion of the study will enroll approximately 450 subjects. Furthermore, Altasciences is pleased to support ReAlta Life Sciences by conducting a Phase I trial to evaluate RLS-0071 for treatment of Acute Lung Injury (ALI) as a result of viral infections, such as COVID-19, respiratory syncytial virus (RSV), and influenza. As part of the ReAlta ALI program underway, the Phase I trial is a single-ascending dose, randomized, double-blind, placebo-controlled, adaptive-design study to evaluate the safety, tolerability, PK, and PD of RLS-0071 in healthy subjects, performed at the Altasciences clinical pharmacology unit in Montreal, Canada.
![](https://www.theinsightpartners.com//assets/rdimages/25434-img1.png)
Get more information on this report :
Market Overview and Dynamics
The North America acute lung injury market is expected to grow from US$ 201.93 million in 2021 to US$ 280.16 million by 2028; it is estimated to grow at a CAGR of 4.8% from 2021 to 2028. Manufacturers in the acute lung injury treatment market are focusing on the adoption of various strategies such as product innovation, product launches, and approvals, as well as R&D investment for advancements, along with inorganic strategies such as merger and acquisition and partnerships as their developmental strategies to maintain the competitive environment in the market. For instance, Faron Pharmaceuticals, Ltd. Is engaged in developing pharmacological treatments for ALI with the help of a consortium. The FP-1201-lyo treatment for acute lung injury is in the third phase of clinical trials and is anticipated to obtain marketing authorization during the forecast period. Similarly, in November 2020, Novartis entered into an exclusive license with Mesoblast to manufacture, develop, and commercialize remestemcel-L to treat ARDS associated with COVID-19. Moreover, recent advances in understanding ALI pathophysiology have led to investigations of numerous potential pharmacologic treatments. Therefore, the introduction of advanced products is likely to revolutionize and offer opportunities for the growth of the North America acute lung injury market.
Key Market Segments
In terms of therapy, the mechanical ventilation segment accounted for the largest share of the North America acute lung injury market in 2020. In terms of end user, the hospitals segment held a larger market share of the North America acute lung injury market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the North America acute lung injury market are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are Angion; Asklepion Pharmaceuticals, LLC.; GlaxoSmithKline Plc; Qx Therapeutics, Inc.; ReAlta Life Sciences, Inc.; Stemedica Cell Technologies, Inc; and Windtree Therapeutics, Inc.
Reasons to buy report
- To understand the North America acute lung injury market landscape and identify market segments that are most likely to guarantee a strong return
- Stay ahead of the race by comprehending the ever-changing competitive landscape for North America acute lung injury market
- Efficiently plan M&A and partnership deals North America acute lung injury market by identifying market segments with the most promising probable sales
- Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America acute lung injury market
- Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
North America Acute Lung Injury Market Segmentation
North America Acute Lung Injury Market - By Therapy
- Mechanical Ventilation
- Fluid Management
- Pharmacotherapy
- Adjunctive Procedures
North America Acute Lung Injury Market - By End User
- Hospitals
- Ambulatory Surgery Centers
- Others
North America Acute Lung Injury Market - By Country
- US
- Canada
- Mexico
North America Acute Lung Injury Market - Company Profiles
- Angion
- Asklepion Pharmaceuticals, LLC.
- GlaxoSmithKline Plc
- Qx Therapeutics, Inc.
- ReAlta Life Sciences, Inc.
- Stemedica Cell Technologies, Inc
- Windtree Therapeutics, Inc.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 North America Acute Lung Injury Market – By Therapy
1.3.2 North America Acute Lung Injury Market – By End User
1.3.3 North America Acute Lung Injury Market– By Country
2. Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Acute Lung Injury Market– Market Landscape
4.1 Overview
4.2 North America PEST Analysis
4.3 Experts Opinion
5. North America Acute Lung Injury Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Respiratory Diseases
5.1.2 Growing Geriatric Population
5.2 Market Restraints
5.2.1 Expensive Therapies
5.3 Market Opportunities
5.3.1 Increasing Technological Advancements by Market Players
5.4 Future Trends
5.4.1 Surging Pipeline Drugs
5.5 Impact Analysis
6. Acute Lung Injury Market– North America Analysis
6.1 North America Acute Lung Injury Market Revenue Forecast and Analysis
7. North America Acute Lung Injury Market Analysis – By Therapy
7.1 Overview
7.2 North America Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)
7.3 Mechanical Ventilation
7.3.1 Overview
7.3.2 Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Fluid Management
7.4.1 Overview
7.4.2 Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Pharmacotherapy
7.5.1 Overview
7.5.2 Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Adjunctive Procedures
7.6.1 Overview
7.6.2 Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8. North America Acute Lung Injury Market Analysis – By End User
8.1 Overview
8.2 North America Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)
8.3 Hospitals
8.3.1 Overview
8.3.2 Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Ambulatory Surgery Centers
8.4.1 Overview
8.4.2 Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
9. North America Acute Lung Injury Market – Country Analysis
9.1 North America: Acute Lung Injury Market
9.1.1 Overview
9.1.2 North America: Acute Lung Injury Market, by Country, 2021 & 2028 (%)
9.1.2.1 US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.1 US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.2 US Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.1.3 US Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)
9.1.2.2 Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.1 Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.2 Canada Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.2.3 Canada Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)
9.1.2.3 Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.1 Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.2 Mexico Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
9.1.2.3.3 Mexico Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)
10. Impact Of COVID-19 Pandemic on North America Acute Lung Injury Market
10.1 North America: Impact Assessment of COVID-19 Pandemic
11. Industry Landscape
11.1 Overview
11.2 Organic Developments
11.2.1 Overview
11.3 Inorganic Developments
11.3.1 Overview
12. Company Profiles
12.1 GlaxoSmithKline Plc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Stemedica Cell Technologies, Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Windtree Therapeutics, Inc.
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ReAlta Life Sciences, Inc.
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Qx Therapeutics, Inc.
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Angion
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Asklepion Pharmaceuticals, LLC.
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. North America Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Table 2. US Acute Lung Injury Market, by Therapy – Revenue and Forecast to 2028 (USD Million)
Table 3. US Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 4. Canada Acute Lung Injury Market, by Therapy -Revenue and Forecast to 2028 (USD Million)
Table 5. Canada Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 6. Mexico Acute Lung Injury Market, by Therapy -Revenue and Forecast to 2028 (USD Million)
Table 7. Mexico Acute Lung Injury Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 8. Organic Developments Done by Companies
Table 9. Inorganic Developments Done by Companies
Table 10. Glossary of Terms
LIST OF FIGURES
Figure 1. North America Acute Lung Injury Market Segmentation
Figure 2. North America Acute Lung Injury Market Segmentation, By Country
Figure 3. North America Acute Lung Injury Market Overview
Figure 4. Mechanical Ventilation Segment Held the Largest Share of the Market in 2021
Figure 5. The US to Show Significant Growth During Forecast Period
Figure 6. North America PEST Analysis
Figure 7. North America Acute Lung Injury Market Impact Analysis of Driver and Restraints
Figure 8. North America Acute Lung Injury Market– Revenue Forecast and Analysis
Figure 9. North America Acute Lung Injury Market Revenue Share, by Therapy (2021 and 2028)
Figure 10. North America Mechanical Ventilation: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 11. North America Fluid Management: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. North America Pharmacotherapy: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. North America Adjunctive Procedures: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. North America Acute Lung Injury Market Revenue Share, by End User (2021 and 2028)
Figure 15. North America Hospitals: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. North America Ambulatory Surgery Centers: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. North America Others: Acute Lung Injury Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. North America: Acute Lung Injury Market, by Key Country – Revenue (2021) (USD Million)
Figure 19. North America: Acute Lung Injury Market, by Country, 2021 & 2028 (%)
Figure 20. US: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 21. Canada: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 22. Mexico: Acute Lung Injury Market – Revenue and Forecast to 2028 (USD Million)
Figure 23. Impact of COVID-19 Pandemic in North American Country Markets
- Angion
- Asklepion Pharmaceuticals, LLC.
- GlaxoSmithKline Plc
- Qx Therapeutics, Inc.
- ReAlta Life Sciences, Inc.
- Stemedica Cell Technologies, Inc
- Windtree Therapeutics, Inc.
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America acute lung injury market.
- Highlights key business priorities in order to assist companies to realign their business strategies
- The key findings and recommendations highlight crucial progressive industry trends in the North America acute lung injury market, thereby allowing players across the value chain to develop effective long-term strategies
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the acute lung injury market, as well as those hindering it
- Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution